Hoption Cann, S. A., van Netten, J. P. & van Netten, C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad. Med. J. 79, 672–680 (2003).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butts, C. et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 59–68 (2014).

Article  CAS  PubMed  Google Scholar 

Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yarchoan, M., Johnson, B. A. 3rd, Lutz, E. R., Laheru, D. A. & Jaffee, E. M. Targeting neoantigens to augment antitumour immunity. Nat. Rev. Cancer 17, 569 (2017).

Article  CAS  PubMed  Google Scholar 

Cottrell, T. R. et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann. Oncol. 29, 1853–1860 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strauss, L. et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci. Immunol. 5, eaay1863 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632–644 (2024). This work is the first randomized phase IIb trial to demonstrate that personalized mRNA vaccine plus anti-PD1 versus anti-PD1 alone induced greater recurrence-free survival in patients with resected melanoma.

Article  CAS  PubMed  Google Scholar 

Raskov, H., Orhan, A., Christensen, J. P. & Gogenur, I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359–367 (2021).

Article  CAS  PubMed  Google Scholar 

Roy, V. et al. Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination. NPJ Vaccines 8, 39 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al Bakir, M. et al. Clonal driver neoantigen loss under EGFR TKI and immune selection pressures. Nature 639, 1052–1059 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huff, A. L. et al. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight 8, e174027 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Dolina, J. S. et al. Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression. J. Clin. Invest. 133, e164258 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696–701 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown, T. A. 2nd et al. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res. Treat. 181, 391–401 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Huff, A. L., Jaffee, E. M. & Zaidi, N. Messenger RNA vaccines for cancer immunotherapy: progress promotes promise. J. Clin. Invest. 132, e156211 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabbatini, P. et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 18, 6497–6508 (2012).

Article  CAS  PubMed  Google Scholar 

Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107–112 (2020). This work is the first phase I trial testing and demonstrating feasibility and immunogenicity of mRNA personalized vaccine in patients with melanoma who had been treated with ICI.

Article  CAS  PubMed  Google Scholar 

Cathcart, K. et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103, 1037–1042 (2004).

Article  CAS  PubMed  Google Scholar 

Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408–2417 (2006).

Article  CAS  PubMed  Google Scholar 

Orlen, M. I. et al. T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-24-1475 (2025).

Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042–1051 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639, 474–482 (2025).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347–362.e24 (2020).

Article  CAS  PubMed  Google Scholar 

Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531–542 (2024). This phase I trial demonstrates immunogenicity and clinical activity of an off-the-shelf peptide vaccine targeting mutant KRAS neoantigens in patients with resected pancreatic and colon cancers.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang, J. T., Wherry, E. J. & Goldrath, A. W. Molecular regulation of effector and memory T cell differentiation. Nat. Immunol. 15, 1104–1115 (2014).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mami-Chouaib, F. et al. Resident memory T cells, critical components in tumor immunology. J. Immunother. Cancer 6, 87 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Baharom, F. et al. Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells. Nat. Immunol. 22, 41–52 (2021).

Article  CAS  PubMed  Google Scholar 

Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360–378 (2021).

Article  CAS  PubMed  Google Scholar 

Steinman, R. M. & Pope, M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109, 1519–1526 (2002).

Article  CAS  PubMed  PubMed Central